Thymalin as a Potential Alternative in the Treatment of Severe Acute Respiratory Infection Associated with SARS-CoV-2
A Lukyanov Sergey, Isakovich Boris, G Shapovalov Konstantin et al.
Research Article — Peer-Reviewed Source
Original research published by Sergey et al. in International Journal of Immunology and Immunotherapy. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
Polypeptide medication Thymalin obtained from the calf thymus has beneficial effects on cell-mediated immunity and blood coagulation. Here we present a patient with COVID-19 severe pneumonia, who has first treated with Lopinavir/Ritonavir + hydroxychloroquine without clinical benefit; and was then given Thymalin treatment with impressive clinical and laboratory improvement.
Full text is available at the publisher.
Read at Publisher| DOI | 10.23937/2378-3672/1410055 |
| Journal | International Journal of Immunology and Immunotherapy |
| Year | 2020 |
| Authors | A Lukyanov Sergey, Isakovich Boris, G Shapovalov Konstantin, K Khavinson Vladimir, N Smolyakov Yuri, K Tereshkov Pavel, Kazuyo Yuri, Antoine Valéry, Eli Magen |
| License | Open Access — see publisher for license terms |
| Citations | 1 |